Journal of Clinical Oncology & Advanced Therapy

Abstract

Mohs micrographic surgery is widely regarded as the surgical gold standard for the treatment of non-melano ma skin cancers (NMSC). It offers high cure rates, meticulous margin control, and well-established oncologic reliability. However, the increasing availability of molecularly targeted therapies invites critical re-examina tion of whether surgical excision must always define “complete cancer removal.” Curaderm, a topical therapy containing the solasodine rhamnoside glycoalkaloid complex BEC, presents a fundamentally different approach. Its mechanism - selective induction of apoptosis in cancer cells through binding to mutant rhamnose-binding receptors – differs markedly from the tissue-removal paradigm of Mohs surgery. Comparison of these two modalities highlights a conceptual disconnect between traditional surgical clearance and modern molecular-cellular selectivity. This communication examines that disconnect and argues that the standards for skin cancer clearance should evolve to include non-surgical, targeted cellular therapies capable of achieving comparable oncologic effica cy with superior tissue preservation.